We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Choose among 20-plus deals—big, like the GSK-Novartis asset swap, and smaller buys such as Bristol-Myers' Medarex buyout—for best and worst of the past 10 years.